Advertisement

Gastric Cancer in the Elderly

  • Emily McCracken
  • Sarah Hatch
  • Dan G. BlazerIII
Living reference work entry

Abstract

Gastric cancer is the fourth most common cancer worldwide and the second leading cause of cancer death, representing a major contributor to the global health cancer burden. In the Western world, gastric cancer has been on the decline overall but remains a significant risk factor in the elderly population. This chapter will review the epidemiology, diagnosis, and treatment of gastric cancer in the elderly. Emphasis will be placed on landmark clinical trials which guide current surgical management and perioperative therapy decision-making. Up-to-date management recommendations from the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) will be integrated in the discussion. Special focus will be given to issues relating to advanced age and how these issues impact decision-making for oncologists managing this growing patient population.

Keywords

Gastric cancer Geriatric surgery Total gastrectomy Partial gastrectomy Subtotal gastrectomy Frailty Elderly Gastric adenocarcinoma 

References

  1. 1.
    Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar MH, Hancock J, Hay RJ, Hunter-Merrill R, Huynh C, Hosgood HD, Johnson CO, Jonas JB, Khubchandani J, Kumar GA, Kutz M, Lan Q, Larson HJ, Liang X, Lim SS, Lopez AD, MacIntyre MF, Marczak L, Marquez N, Mokdad AH, Pinho C, Pourmalek F, Salomon JA, Sanabria JR, Sandar L, Sartorius B, Schwartz SM, Shackelford KA, Shibuya K, Stanaway J, Steiner C, Sun J, Takahashi K, Vollset SE, Vos T, Wagner JA, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed MB, Alabed S, Alam NK, Aldhahri SF, Alem G, Alemayohu MA, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem HB, Barac A, Bedi N, Bensenor I, Berhane A, Bernabé E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castañeda-Orjuela C, Catalá-López F, Chiang P, Chibueze C, Chitheer A, Choi J-Y, Cowie B, Damtew S, das Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries AY, Farvid M, Farzadfar F, Fernandes J, Fischer F, G/Hiwot TT, Gebru A, Gopalani S, Hailu A, Horino M, Horita N, Husseini A, Huybrechts I, Inoue M, Islami F, Jakovljevic M, James S, Javanbakht M, Jee SH, Kasaeian A, Kedir MS, Khader YS, Khang Y-H, Kim D, Leigh J, Linn S, Lunevicius R, El Razek HMA, Malekzadeh R, Malta DC, Marcenes W, Markos D, Melaku YA, Meles KG, Mendoza W, Mengiste DT, Meretoja TJ, Miller TR, Mohammad KA, Mohammadi A, Mohammed S, Moradi-Lakeh M, Nagel G, Nand D, Le Nguyen Q, Nolte S, Ogbo FA, Oladimeji KE, Oren E, Pa M, Park E-K, Pereira DM, Plass D, Qorbani M, Radfar A, Rafay A, Rahman M, Rana SM, Søreide K, Satpathy M, Sawhney M, Sepanlou SG, Shaikh MA, She J, Shiue I, Shore HR, Shrime MG, So S, Soneji S, Stathopoulou V, Stroumpoulis K, Sufiyan MB, Sykes BL, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tessema GA, Thakur JS, Tran BX, Ukwaja KN, Uzochukwu BSC, Vlassov VV, Weiderpass E, Wubshet Terefe M, Yebyo HG, Yimam HH, Yonemoto N, Younis MZ, Yu C, Zaidi Z, Zaki MES, Zenebe ZM, Murray CJL, Naghavi M (2016) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 388:1459–1544.  https://doi.org/10.1001/jamaoncol.2016.5688 Google Scholar
  2. 2.
    Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H (2016) Gastric cancer. Lancet 388:2654–2664.  https://doi.org/10.1016/S0140-6736(16)30354-3 CrossRefPubMedGoogle Scholar
  3. 3.
    Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30.  https://doi.org/10.3322/caac.21332 CrossRefPubMedGoogle Scholar
  4. 4.
    Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Kosary C, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D, Chen H, Feuer E, Cronin K (eds) (2017) SEER cancer statistics review, 1975–2014. National Cancer Institute, BethesdaGoogle Scholar
  5. 5.
    Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D (2016) Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v38–v49.  https://doi.org/10.1093/annonc/mdw350 CrossRefPubMedGoogle Scholar
  6. 6.
    Herrero R, Park JY, Forman D (2014) The fight against gastric cancer – the IARC working group report. Best Pract Res Clin Gastroenterol 28:1107–1114.  https://doi.org/10.1016/j.bpg.2014.10.003 CrossRefPubMedGoogle Scholar
  7. 7.
    Blot WJ (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA J Am Med Assoc 265:1287.  https://doi.org/10.1001/jama.1991.03460100089030 CrossRefGoogle Scholar
  8. 8.
    Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, Anderson RN, Ma J, Ly KN, Cronin KA, Penberthy L, Kohler BA (2016) Annual report to the Nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer 122:1312–1337.  https://doi.org/10.1002/cncr.29936 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New YorkGoogle Scholar
  10. 10.
    Saif MW, Makrilia N, Zalonis A, Merikas M, Syrigos K (2010) Gastric cancer in the elderly: an overview. Eur J Surg Oncol 36:709–717.  https://doi.org/10.1016/j.ejso.2010.05.023 CrossRefPubMedGoogle Scholar
  11. 11.
    Atherton JC (2006) The pathogenesis of helicobacter pylori–induced gastro-duodenal diseases. Annu Rev Pathol Mech Dis 1:63–96.  https://doi.org/10.1146/annurev.pathol.1.110304.100125 CrossRefGoogle Scholar
  12. 12.
    Rugge M, Fassan M, Graham DY (2015) Epidemiology of gastric cancer. Gastric Cancer Princ Pract 12:23–34.  https://doi.org/10.1007/978-3-319-15826-6_2 CrossRefGoogle Scholar
  13. 13.
    Fakhouri THI, Ogden CL, Carroll MD, Kit BK, Flegal KM (2012) Prevalence of obesity among older adults in the United States, 2007-2010. NCHS Data Brief 106:1–8Google Scholar
  14. 14.
    Tramacere I, Negri E, Pelucchi C, Bagnardi V, Rota M, Scotti L, Islami F, Corrao G, La vecchia C, Boffetta P (2012) A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol 23:28–36.  https://doi.org/10.1093/annonc/mdr135 CrossRefPubMedGoogle Scholar
  15. 15.
    Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457–1459.  https://doi.org/10.1046/j.1365-2168.1998.00940.x CrossRefPubMedGoogle Scholar
  16. 16.
    Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D’Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VEM, Washington MK, Willett C, Wood DE, Wright CD, Yang G (2016) Gastric cancer: clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw 14:1286–1312CrossRefGoogle Scholar
  17. 17.
    Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49CrossRefPubMedGoogle Scholar
  18. 18.
    Bosman F, Carneiro F, Hruban R, Theise N (2010) WHO classification of tumours of the digestive system: WHO/IARC classification of tumours, 4th edn. WHO Press, LyonGoogle Scholar
  19. 19.
    Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, Hinoue T, Laird PW, Curtis C, Shen H, Weisenberger DJ, Schultz N, Shen R, Weinhold N, David PM (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202–209.  https://doi.org/10.1038/nature13480 CrossRefPubMedCentralGoogle Scholar
  20. 20.
    D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS (2004) Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 240:808–816.  https://doi.org/10.1097/01.sla.0000143245.28656.15 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    El Abiad R, Gerke H (2012) Gastric cancer: endoscopic diagnosis and staging. Surg Oncol Clin N Am 21:1–19.  https://doi.org/10.1016/j.soc.2011.09.002 CrossRefPubMedGoogle Scholar
  22. 22.
    Mocellin S, Pasquali S (2015) Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev 2:CD009944.  https://doi.org/10.1002/14651858.CD009944.pub2 Google Scholar
  23. 23.
    Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS (2006) Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg 191:134–138.  https://doi.org/10.1016/j.amjsurg.2005.10.015 CrossRefPubMedGoogle Scholar
  24. 24.
    Etzioni D, Liu JH, Maggard M, Ko CY (2003) The aging population and its impact on the surgery workforce. Ann Surg 238:170–177.  https://doi.org/10.1097/01.SLA.0000081085.98792.3d PubMedPubMedCentralGoogle Scholar
  25. 25.
    Colby SL, Ortman JM (2014) The baby boom cohort in the United States: 2012 to 2060. US Census Bur Curr Popul Reports P25-1141:1–16Google Scholar
  26. 26.
    Vincent GK, Velkoff VA (2010) The next four decades: the older population in the United States: 2010 to 2050. US Census Bur Curr Popul Reports P25-1138:1–14Google Scholar
  27. 27.
    Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G (2004) Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. Journals Gerontol – Ser A Biol Sci Med Sci 59:255–263.  https://doi.org/10.1093/gerona/59.3.M255 CrossRefGoogle Scholar
  28. 28.
    Tegels JJ, Stoot JH (2015) Way forward: geriatric frailty assessment as risk predictor in gastric cancer surgery. World J Gastrointest Surg 7:223–225.  https://doi.org/10.4240/wjgs.v7.i10.223 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Pujara D, Mansfield P, Ajani J, Blum M, Elimova E, Chiang YJ, Das P, Badgwell B (2015) Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. J Surg Oncol 112:883–887.  https://doi.org/10.1002/jso.24077 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Tegels JJW, de Maat MFG, Hulsewé KWE, Hoofwijk AGM, Stoot JHMB (2014) Value of geriatric frailty and nutritional status assessment in predicting postoperative mortality in gastric cancer surgery. J Gastrointest Surg 18:439–446.  https://doi.org/10.1007/s11605-013-2443-7 CrossRefPubMedGoogle Scholar
  31. 31.
    Partridge JSL, Harari D, Martin FC, Dhesi JK (2014) The impact of pre-operative comprehensive geriatric assessment on postoperative outcomes in older patients undergoing scheduled surgery: a systematic review. Anaesthesia 69:8–16.  https://doi.org/10.1111/anae.12494 CrossRefPubMedGoogle Scholar
  32. 32.
    Chow WB, Rosenthal RA, Merkow RP, Ko CY, Esnaola NF (2012) Optimal preoperative assessment of the geriatric surgical patient: a best practices guideline from the American college of surgeons national surgical quality improvement program and the American geriatrics society. J Am Coll Surg 215:453–466.  https://doi.org/10.1016/j.jamcollsurg.2012.06.017 CrossRefPubMedGoogle Scholar
  33. 33.
    Kim S-W, Han H-S, Jung H-W, Kim K-I, Hwang DW, Kang S-B, Kim C-H (2014) Multidimensional frailty score for the prediction of postoperative mortality risk. JAMA Surg 149:633–640.  https://doi.org/10.1001/jamasurg.2014.241 CrossRefPubMedGoogle Scholar
  34. 34.
    Yang R, Wolfson M, Lewis MC (2011) Unique aspects of the elderly surgical population: an anesthesiologist’s perspective. Geriatr Orthop Surg Rehabil 2:56–64.  https://doi.org/10.1177/2151458510394606 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Badgwell B, Stanley J, Chang GJ, Katz MHG, Lin HY, Ning J, Klimberg SV, Cormier JN (2013) Comprehensive geriatric assessment of risk factors associated with adverse outcomes and resource utilization in cancer patients undergoing abdominal surgery. J Surg Oncol 108:182–186.  https://doi.org/10.1002/jso.23369 CrossRefPubMedGoogle Scholar
  36. 36.
    Starr KNP, Mcdonald SR, Bales CW (2015) Nutritional vulnerability in older adults: a continuum of concerns. Curr Nutr Rep 4:176–184.  https://doi.org/10.1007/s13668-015-0118-6.Nutritional CrossRefGoogle Scholar
  37. 37.
    Tegels JJW, Hulsewé KWE, Sosef MN, Stoot JHMB (2015) Morbidity and mortality after total gastrectomy for gastric malignancy: do not forget about geriatric frailty and nutrition. Surgery 157:406–407.  https://doi.org/10.1016/j.surg.2014.10.021 CrossRefPubMedGoogle Scholar
  38. 38.
    Wagner D, DeMarco MM, Amini N, Buttner S, Segev D, Gani F, Pawlik TM (2016) Role of frailty and sarcopenia in predicting outcomes among patients undergoing gastrointestinal surgery. World J Gastrointest Surg 8:27–40.  https://doi.org/10.4240/wjgs.v8.i1.27 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Papenfuss W, Kukar M, Oxenberg J, Attwood K, Nurkin S, Malhotra U, Wilkinson NW (2014) Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol 21:3008–3014.  https://doi.org/10.1245/s10434-014-3664-z CrossRefPubMedGoogle Scholar
  40. 40.
    Choe Y-R, Joh J-Y, Kim Y-P (2017) Association between frailty and readmission within one year after gastrectomy in older patients with gastric cancer. J Geriatr Oncol.  https://doi.org/10.1016/j.jgo.2017.02.002
  41. 41.
    Kodama Y, Sugimachi K, Soejima K, Matsusaka T, Inokuchi K (1981) Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 5:241–246CrossRefPubMedGoogle Scholar
  42. 42.
    Bonenkamp J, Hermans J, Sasako M, van de Velde C (1999) Extended lymph-node dissection for gastric cancer. N Engl J Med 340:908–914CrossRefPubMedGoogle Scholar
  43. 43.
    Hartgrink H, Van De Velde C, Putter H, Bonenkamp J, Klein Kranenbarg E, Songun I, Welvaart K, Van Krieken J, Meijer S, Plukker J, Van Elk P, Obertop H, Gouma DJ, Van Lanschot J, Taat C, De Graaf P, Von Meyenfeldt M, Tilanus H, Sasako M (2004) Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 22:2069–2077.  https://doi.org/10.1200/JCO.2004.08.026 CrossRefPubMedGoogle Scholar
  44. 44.
    Songun I, Putter H, Kranenbarg EM-K, Sasako M, van de Velde CJH (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439–449.  https://doi.org/10.1016/S1470-2045(10)70070-X CrossRefPubMedGoogle Scholar
  45. 45.
    Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P (1999) Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical co-operative group. Br J Cancer 79:1522–1530.  https://doi.org/10.1016/S0959-8049(01)80998-9 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, Borasi A, Capussotti L, Fronda G, Morino M (2014) Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg 101:23–31.  https://doi.org/10.1002/bjs.9345 CrossRefPubMedGoogle Scholar
  47. 47.
    Schwarz RE, Smith DD (2007) Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg 11:1384–1394.  https://doi.org/10.1007/s11605-007-0264-2 CrossRefPubMedGoogle Scholar
  48. 48.
    Huscher CGS, Mingoli A, Sgarzini G, Sansonetti A, Di Paola M, Recher A, Ponzano C (2005) Laparoscopic versus open subtotal gastrectomy for distal gastric cancer. Ann Surg 241:232–237.  https://doi.org/10.1097/01.sla.0000151892.35922.f2 CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Kelly KJ, Selby L, Chou JF, Dukleska K, Capanu M, Coit DG, Brennan MF, Strong VE (2015) Adenocarcinoma in the west: a case – control study. Ann Surg Oncol 22:3590–3596.  https://doi.org/10.1245/s10434-015-4381-y CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Strong VE (2014) Defining the role of laparoscopic gastrectomy for gastric cancer. J Clin Oncol 32:613–614.  https://doi.org/10.1200/JCO.2013.52.9479 CrossRefPubMedGoogle Scholar
  51. 51.
    Cassidy MR, Gholami S, Strong VE (2017) Minimally invasive surgery: the emerging role in gastric cancer. Surg Oncol Clin N Am 26:193–212.  https://doi.org/10.1177/1938640012445565 CrossRefPubMedGoogle Scholar
  52. 52.
    Kattan MW, Karpeh MS, Mazumdar M, Brennan MF (2003) Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 21:3647–3650.  https://doi.org/10.1200/JCO.2003.01.240 CrossRefPubMedGoogle Scholar
  53. 53.
    Winslet MC, Mohsen YMA, Powell J, Allum WH, Fielding JWL, Hospital RF, Street P, Elizabeth Q, Queen H, Medical E (1996) The influence of age on the surgical management of carcinoma of the stomach. Eur J Surg Oncol 22:220–224CrossRefPubMedGoogle Scholar
  54. 54.
    Damhuis RAM, Wereldsma JCJ, Wiggers T (1996) The influence of age on resection rates and postoperative mortality in 6457 patients with colorectal cancer. Int J Color Dis 11:45–48.  https://doi.org/10.1007/s003840050018 Google Scholar
  55. 55.
    Dudeja V, Habermann EB, Zhong W, Tuttle TM, Vickers SM, Jensen EH, Al-Refaie WB (2011) Guideline recommended gastric cancer care in the elderly: insights into the applicability of cancer trials to real world. Ann Surg Oncol 18:26–33.  https://doi.org/10.1245/s10434-010-1215-9 CrossRefPubMedGoogle Scholar
  56. 56.
    Sakurai K, Muguruma K, Nagahara H, Kimura K, Toyokawa T, Amano R, Kubo N, Tanaka H, Ohtani H, Yashiro M, Maeda K, Ohira M, Hirakawa K (2015) The outcome of surgical treatment for elderly patients with gastric carcinoma. J Surg Oncol 111:848–854.  https://doi.org/10.1002/jso.23896 CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Teng A, Bellini G, Pettke E, Passeri M, Lee DY, Rose K, Bilchik AJ, Attiyeh F (2017) Outcomes of octogenarians undergoing gastrectomy performed for malignancy. J Surg Res 207:1–6.  https://doi.org/10.1016/j.jss.2016.08.020 CrossRefPubMedGoogle Scholar
  58. 58.
    Wang J, Zhang S, Zhang N, Wu Z, Feng J, Ying L, Zhang J (2016) Laparoscopic gastrectomy versus open gastrectomy for elderly patients with gastric cancer: a systematic review and meta-analysis. World J Surg Oncol 14:1–10.  https://doi.org/10.1186/s12957-016-0859-8 Google Scholar
  59. 59.
    Deng Y, Zhang Y, Guo TK (2015) Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: a meta-analysis based on seven randomized controlled trials. Surg Oncol 24:71–77.  https://doi.org/10.1016/j.suronc.2015.02.003 CrossRefPubMedGoogle Scholar
  60. 60.
    Lowy M, Feig BW, Janjan N, Rich T, Pisters PW, Ajani J, Mansfield PF (2001) A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 8:519–524.  https://doi.org/10.1245/aso.2001.8.6.519 CrossRefPubMedGoogle Scholar
  61. 61.
    Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730.  https://doi.org/10.1056/NEJMoa010187 CrossRefPubMedGoogle Scholar
  62. 62.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20.  https://doi.org/10.1056/NEJMoa055531 CrossRefPubMedGoogle Scholar
  63. 63.
    Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, Goto M, Sasaki M (1999) Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet 354:273–277.  https://doi.org/10.1016/S0140-6736(99)01048-X CrossRefPubMedGoogle Scholar
  64. 64.
    Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820CrossRefPubMedGoogle Scholar
  65. 65.
    Bang Y, Kim Y, Yang H, Chung HC, Park Y, Lee KH, Lee K, Kim YH, Noh S (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315–321.  https://doi.org/10.1016/S0140-6736(11)61873-4 CrossRefPubMedGoogle Scholar
  66. 66.
    Lewis BJH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383–1389.  https://doi.org/10.1200/JCO.2003.08.010 CrossRefPubMedGoogle Scholar
  67. 67.
    Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061–2067CrossRefPubMedGoogle Scholar
  68. 68.
    Xiang XJ, Zhang L, Qiu F, Yu F, Zhan ZY, Feng M, Yan J, Zhao JG, Xiong JP (2012) A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients. Chemotherapy 58:1–7.  https://doi.org/10.1159/000335585 CrossRefPubMedGoogle Scholar
  69. 69.
    Lee J, Kang Y, Kang HJ, Lee K, Zang DY, Ryoo B, Kim JG, Park SR, Kang WK, Shin DB, Ryu M, Chang HM, Kim T, Baek JH, Min YJ (2008) A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer clinical studies. Br J Canc 99:584–590.  https://doi.org/10.1038/sj.bjc.6604536 CrossRefGoogle Scholar
  70. 70.
    Catalano V, Bisonni R, Graziano F, Giordani P, Alessandroni P, Baldelli AM, Casadei V, Rossi D, Fedeli SL, D’Emidio S, Giustini L, Fiorentini G (2013) A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer 16:411–419.  https://doi.org/10.1007/s10120-012-0204-z CrossRefPubMedGoogle Scholar
  71. 71.
    Trumper M, Ross PJ, Cunningham D, Norman AR, Hawkins R, Seymour M, Harper P, Iveson T, Nicolson M, Hickish T (2006) Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer 42:827–834.  https://doi.org/10.1016/j.ejca.2005.08.044 CrossRefPubMedGoogle Scholar
  72. 72.
    Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE (2010) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 17:CD004064.  https://doi.org/10.1002/14651858.CD004064.pub3.www.cochranelibrary.com Google Scholar
  73. 73.
    Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163–168.  https://doi.org/10.1023/A:1008243606668 CrossRefPubMedGoogle Scholar
  74. 74.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697.  https://doi.org/10.1016/S0140-6736(10)61121-X CrossRefPubMedGoogle Scholar
  75. 75.
    Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39.  https://doi.org/10.1016/S0140-6736(13)61719-5 CrossRefPubMedGoogle Scholar
  76. 76.
    Wilke H, Muro K, Cutsem E Van, Oh S-C, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim T-Y, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235. doi: https://doi.org/10.1016/S1470-2045(14)70420-6
  77. 77.
    Miner TJ, Jaques DP, Karpeh MS, Brennan MF (2004) Defining palliative surgery in patients receiving noncurative resections for gastric cancer. J Am Coll Surg 198:1013–1021.  https://doi.org/10.1016/j.jamcollsurg.2004.02.007 CrossRefPubMedGoogle Scholar
  78. 78.
    Wan Q-S, Zhang K-H (2016) Noninvasive detection of gastric cancer. Tumor Biol 37:11633–11643.  https://doi.org/10.1007/s13277-016-5129-4 CrossRefGoogle Scholar
  79. 79.
    Berstrom N, Braden BJ, Laguzza A, Holman V (1987) The braden scale for predicting pressure sore risk. Nurs Res 36:205–210.  https://doi.org/10.1097/01.ASW.0000411403.11392.10 CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Emily McCracken
    • 1
  • Sarah Hatch
    • 2
  • Dan G. BlazerIII
    • 1
  1. 1.Department of SurgeryDuke University Medical CenterDurhamUSA
  2. 2.The Ohio State University School of MedicineOhio State UniversityColumbusUSA

Section editors and affiliations

  • Jason Johanning
    • 1
  • Sandhya Lagoo-Deenadayalan
    • 2
  1. 1.Department of SurgeryUniversity of Nebraska Medical CenterOmahaUSA
  2. 2.Duke MedicineDurhamUSA

Personalised recommendations